Experts discuss how seborrheic dermatitis can be distinguished from atopic dermatitis and psoriasis through clinical features and underlying immune patterns, highlighting the role of Th17/Th22-driven inflammation and barrier dysfunction in guiding more precise, targeted treatment strategies.
Experts discuss how seborrheic dermatitis arises from a multifactorial interplay of immune dysregulation, Malassezia yeast colonization, epidermal barrier impairment, and sebaceous gland activity, shaping its chronic nature and informing targeted treatment approaches.
Experts discuss the complexities of treating psoriatic arthritis, emphasizing the need for a multifaceted approach and potential medication switches.
Explore the complexities of managing psoriatic arthritis in dermatology, focusing on effective treatment strategies and patient care insights.
Patient advocate Suki Tipp details her progression from misattributed cutaneous findings and fragmented specialty care to life-threatening anaphylaxis and eventual disease control with targeted therapy.
Thrasyvoulos Tzellos, MD, PhD, explains HS’s progressive toll and how UCB’s BE HEARD bimekizumab data shows durable tunnel reduction and lasting disease improvement.
In a conversation with Dermatology Times, Del Rosso highlighted the growing range of systemic and procedural therapies available to clinicians.
Systemic mastocytosis often hides behind common symptoms; learn why early, team-based diagnosis and tailored staging prevent delays and risks.
Michael O’Donoghue, MD, outlines how delegating PDT workflows to trained medical assistants can preserve physician time while maintaining treatment quality.
Neal Bhatia, MD, explores denifanstat for acne—oral FASN inhibition that curbs sebum, boosts outcomes, and may be an alternative to antibiotics or retinoids.
BEACON phase 2 shows brepocitinib delivers dramatic, low-placebo CSAMI improvements with strong safety, Misha Rosenbach, MD reports, boosting hope for cutaneous sarcoidosis.
At the 2026 South Beach Symposium, Joel Claveau, MD, emphasized that accurate early diagnosis and proper staging are the cornerstones of effective melanoma management.
Todd Schlesinger, MD, highlights data supporting red light–activated PDT with 10% ALA gel for superficial basal cell carcinoma, discussing structured treatment protocols and manageable tolerability.
Misha Rosenbach, MD, discussed the burden of cutaneous sarcoidosis (CS) and how emerging therapies like brepocitinib could fill this clinical need.
Healthcare professionals discuss the complexities of treating psoriasis, emphasizing patient communication and individualized care for optimal outcomes.
Explore the complexities of managing psoriasis in a typical patient, focusing on treatment challenges and psychosocial impacts.
Highlighting conditions like lichen planus, which has no FDA-approved treatments, Lio underscores why clinicians must be comfortable prescribing beyond the label.
As we celebrate Valentine's Day, Mona Shahriari, MD, FAAD; Neal Bhatia, MD; Peter Lio, MD; Lisa Swanson, MD; Lawrence Schachner, MD; Julie Karen, MD; and Glynis Ablon, MD, FAAD, share why they love dermatology.
Learn how skin clues reveal systemic mastocytosis early, from subtypes to KIT D816V mutations that guide targeted treatment.
The 2026 meeting emphasized integrating cutting-edge medical therapies with aesthetic strategies to address both disease control and quality of life.
LILAC data shows litifilimab rapidly improves CLE skin scores, fueling AMETHYST phase 3 and supporting FDA breakthrough for cutaneous lupus patients.
Todd Schlesinger, MD, reviews emerging randomized trial data supporting red light–activated photodynamic therapy with 10% aminolevulinic acid gel and outlines key considerations for patient selection in superficial basal cell carcinoma (sBCC).
Experts discuss effective strategies for managing atopic dermatitis, emphasizing the importance of treatment adherence and quality of life improvements.
Explore effective management strategies for pediatric atopic dermatitis, focusing on treatment options and patient experiences for optimal care.
Todd Schlesinger, MD, discusses emerging evidence, clearance outcomes, and practical considerations for using red light–based photodynamic therapy as a nonsurgical option in select superficial basal cell carcinoma (BCC) cases.
Victoria Werth, MD, highlights CLE treatment gaps and how BDCA2-targeting litifilimab may quickly curb interferon-driven skin disease with less toxicity.
Achieving lower psoriasis levels significantly enhances patients' emotional well-being and overall quality of life, transforming their daily experiences.
Healthcare providers discuss effective communication strategies for explaining treatment goals to patients, emphasizing collaboration and understanding in managing chronic conditions.
Bispecific and trispecific biologics are being developed to achieve deeper clearance and more meaningful symptom relief.
Clinicians are increasingly facing barriers when attempting to prescribe on-label treatments for indicated patients.
